NETRF Announces grant funding for neuroendocrine cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Neuroendocrine Tumor Research Foundation announced its latest Request for Applications and invites innovative research applications in neuroendocrine tumors that can bring the field closer to more effective therapies.

This uncommon cancer occurring in hormone-producing cells is often overlooked for research funding. NETRF serves as the major private funder of NET cancer research.

To ensure that high-quality, meaningful research proposals are selected, NETRF uses a rigorous peer review process, which includes external expert reviewers and a Board of Scientific Advisors.

Interested applicants must submit a letter of intent by June 13. From that pool, exceptional investigators with the most promising and transformative ideas will be invited to submit full proposals. Grant awards will be announced in December 2018.

Last year NETRF invested heavily in a targeted form of radiation called peptide receptor radionuclide therapy.

Since 2005, NETRF has funded $20 million in scientific research grants to expand the molecular understanding of NETs and help drive personalized treatment options for patients. NET research projects have been funded in the U.S., Canada, United Kingdom, Switzerland, Australia, and the Netherlands.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login